Menu
  • Join
  • Login
  • Contact
 

Search abstracts


How does Samsung bioepis rapidly develop and manufacture high quality biosimilars?

  • At: 2017 FIP Congress in Stockholm (Sweden)
  • Type: Presentation
  • By: MIN, Brain Hosumg (Incheon, Korea, Republic Of)
  • Co-author(s): Brain Hosumg Min: Drug Substance Team, Samsung Bioepis, Incheon, Korea, Republic Of
  • Abstract:

    A biosimilar is a biologic product that is highly similar but not identical to its reference product. The biosimilarity between the reference product and its biosimilar is demonstrated by the similarity in their clinical effects, such as efficacy, PK, safety, and immunogenicity. The similar clinical profiles are driven by similar analytical..

  • The access to the whole abstract and the presentation file is available to FIP members and to congress participants of that specific congress. Please login
Last update 4 October 2019

FIP Congresses